POWDERMED
PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.
POWDERMED
Industry:
Health Care Medical Therapeutics
Founded:
2004-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Contact:
+441865501500
Total Funding:
20 M GBP
Similar Organizations
CorneaCare
Personalized dry eye treatment delivered and monitored.
Nobias Therapeutics
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children.
Current Employees Featured
Founder
Investors List
Abingworth
Abingworth investment in Series A - PowderMed
Advent Venture Partners
Advent Venture Partners investment in Series A - PowderMed
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Series A - PowderMed
SV Health Investors
SV Health Investors investment in Series A - PowderMed
Schroder Ventures
Schroder Ventures investment in Series A - PowderMed
More informations about "PowderMed"
PowderMed 2025 Company Profile: Valuation, Investors
PowderMed was founded in 2004. Where is PowderMed headquartered? PowderMed is headquartered in Oxford, United Kingdom. What is the size of PowderMed? PowderMed has …See details»
PowderMed - 2025 Company Profile, Funding & Competitors
PowderMed was known as TRX Pharmaccines Limited till May 2004. Key Metrics. Founded Year. 2004. Location. Oxford, United Kingdom. Stage. Acqui-Hired. Investors. Abingworth & 3 more. …See details»
PowderMed - Abingworth LLP
PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to …See details»
PowderMed - VentureRadar
PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology. PMED delivers DNA vaccines into the skin without needles in a dry powder formulation of gold …See details»
Pfizer agreement to acquire Powdermed Ltd. - Acquisition Marks ...
Oct 10, 2006 PowderMed has DNA-based influenza vaccines in clinical development for prevention of both seasonal and avian flu. The most advanced candidate is entering Phase II …See details»
PowderMed - Products, Competitors, Financials, Employees, …
PowderMed develops vaccine for the treatment of chronic infectious diseases and cancer. The company uses deoxyribonucleic acid (DNA) coated gold particles delivered by a needle-free …See details»
Pfizer acquires PowderMed - Growth Business
Oct 9, 2006 PowderMed has developed technology to deliver DNA directly to the cells of the body’s immune system and is advancing a pipeline of proprietary vaccine candidates for …See details»
PowdermEd.com - AboutUs
PowderMed was founded in May 2004 to develop the proprietary Particle Mediated Epidermal Delivery (PMEDTM) technology. PMED delivers DNA vaccines into the skin without needles in …See details»
Pfizer Inc. Expands Commitment To Fight Infectious Diseases
Oct 9, 2006 Rolf Stahel Chairman of PowderMed Ltd. added, “PowderMed is a great success story. Through the financial support of a syndicate of leading life science investors and an …See details»
New UK-based vaccines firm, PowderMed, spins out from Chiron
May 23, 2004 New UK-based vaccines firm, PowderMed, spins out from Chiron 23 May 2004 PowderMed Ltd, a new UK-based company focused on the development of therapeutic DNA …See details»
Pfizer Breaks into the DNA-based Vaccine Market
Oct 10, 2006 Acquisition of PowderMed adds to company’s pipeline. Pfizer acquired PowderMed, a privately held U.K. company specializing in DNA-based vaccines with a …See details»
Pfizer Purchases PowderMed - biopharminternational.com
Oct 26, 2006 Pfizer has agreed to purchase PowderMed (London, England, www.powdermed.com), a British company that develops DNA-based vaccines.The company …See details»
PowderMed - Funding, Financials, Valuation & Investors
PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology.See details»
PowderMed | Advent Life Sciences
PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology for needle-free delivery of DNA vaccines into the skin as a dry powder formulation of gold particles. CEO …See details»
Pfizer to Acquire PowderMed, Enter DNA-Based Vaccine Market
Oct 12, 2006 PowderMed’s portfolio also includes Phase I formulations for herpes simplex virus (HSV) and chronic hepatitis B (HBV) and a preclinical candidate for treating genital warts …See details»
Powdermed - selectscience.net
Find Powdermed products, product reviews and resources on SelectScience (Opens in new tab) (Opens in new tab) (Opens in new tab) Login Join Free. Fields & Topics. Life Sciences. All …See details»
PowderMed's Vaccines: Out of Chiron, Into the Clinic - In Vivo
Jan 1, 2003 The spinout of PowderJect's DNA vaccine technology following that company's acquisition by Chiron in mid-2003 was no surprise-these powder-injection assets are far too …See details»
PowderMed - Contacts, Employees, Board Members, Advisors
Experience the new Crunchbase, powered by AI . Organization. PowderMedSee details»
PowderMed's Vaccines: Out of Chiron, Into the Clinic
Jun 1, 2004 PowderMed's Vaccines: Out of Chiron, Into the Clinic 01 Jun 2004 The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 …See details»
Mitigating fatigue in long COVID patients with MYPplus: a clinical ...
2 days ago Purpose The COVID-19 pandemic has led to the emergence of a secondary public health crisis known as Long COVID. It is estimated that approximately 10% of individuals who …See details»